Format

Send to

Choose Destination
Curr Chem Genomics. 2012;6:93-102. doi: 10.2174/1875397301206010093. Epub 2012 Dec 31.

A homogenous luminescence assay reveals novel inhibitors for giardia lamblia carbamate kinase.

Author information

1
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

The human pathogen Giardia lamblia is an anaerobic protozoan parasite that causes giardiasis, one of the most common diarrheal diseases worldwide. Although several drugs are available for the treatment of giardisis, resistance to these drugs has been reported and is likely to increase. The Giardia carbamate kinase (glCK) plays an essential role in Giardia metabolism and has no homologs in humans, making it an attractive candidate for anti-Giardia drug development. We have developed a luminescent enzyme coupled assay to measure the activity of glCK by quantitating the amount of ATP produced by the enzyme. This assay is homogeneous and has been miniaturized into a 1536-well plate format. A pilot screen against 4,096 known compounds using this assay yielded a signal-to-basal ratio of 11.5 fold and Z' factor of 0.8 with a hit rate of 0.9 % of inhibitors of glCK. Therefore, this Giardia lamblia carbamate kinase assay is useful for high throughput screening of large compound collection for identification of the inhibitors for drug development.

KEYWORDS:

Carbamate kinase; Giardia; assay development.; high throughput screening

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center